MN-166 (ibudilast) was well tolerated and no safety concerns were observed in the multi-dose study. A preliminary proof-of-concept (POC) study was conducted to determine the feasibility of the second nonclinical model as a tool to evaluate MN-166 (ibudilast) as a MCM for chlorine gas exposure. After multiple attempts by MediciNova's subcontractor to establish the feasibility of the second Cl 2 -gas induced lung injury model, it was not deemed to be a feasible model to evaluate a drug candidate and there are no evaluable efficacy results from the second nonclinical model POC study.